Amount of Central Fat Predicts Mortality Risk in Non-Obese Individuals

CronosTempi · April 2, 2026, 9:54am

Antioxidant activity of blueberry fruit is impaired by association with milk

“When blueberries and milk were ingested there was no increase in plasma antioxidant capacity. There was a reduction in the peak plasma concentrations of caffeic and ferulic acid (-49.7%, p<0.001, and -19.8%, p<0.05, respectively) as well as the overall absorption (AUC) of caffeic acid (p<0.001). The ingestion of blueberries in association with milk, thus, impairs the in vivo antioxidant properties of blueberries and reduces the absorption of caffeic acid.”

Accessible overview:

My own view: maybe, but why take the chance? YMMV.

RapAdmin · April 10, 2026, 7:03pm

#1 Meal to Reverse Belly Visceral Fat FAST

I. Executive Summary

The provided transcript outlines dietary interventions targeting visceral adiposity and non-alcoholic fatty liver disease (NAFLD, recently updated in clinical literature to metabolic dysfunction-associated steatotic liver disease, MASLD). The central thesis posits that hepatic steatosis can be rapidly reversed through specific macronutrient and phytochemical modulations, independently of total body weight loss. The speaker highlights dietary polyphenols, increased protein intake, unsaturated fatty acids, and resistant starch (RS2) as primary effectors for hepatic fat oxidation and the suppression of de novo lipogenesis.

While the narrative is largely grounded in established clinical trials—specifically referencing the DIRECT PLUS trial for the Green Mediterranean diet and the DiRECT trial for extreme hypocaloric interventions—it occasionally conflates acute metabolic ward study results with sustainable outpatient protocols. The introductory assertion that visceral fat can be reversed “in weeks with little to no effort” is a hyperbolic marketing hook that contradicts the high-compliance nature of the cited clinical interventions, such as consuming 100 grams of duckweed daily or adhering to a 600-calorie liquid diet.

From a longevity and biotech perspective, the transcript successfully identifies high-yield metabolic pathways. The emphasis on polyphenol-induced metabolic shifts and the microbiome-mediated effects of resistant starch align with current anti-aging research focusing on metabolic flexibility and insulin sensitivity. Furthermore, the explicit warning regarding saturated fats inducing steatosis more aggressively than simple sugars accurately reflects recent human lipidomics data, challenging prevailing low-carbohydrate orthodoxies.

However, the translational gap remains a practical concern. While specific protocols like the RS2 supplementation demonstrate profound clinical efficacy (a 50% reduction in liver fat), commercial availability and long-term human adherence outside trial settings are highly variable. Ultimately, the interventions discussed present a viable, evidence-based roadmap for metabolic rehabilitation, provided the initial hyperbole is discarded and the protocols are integrated into a rigorous, compliance-driven framework. The core utility lies in leveraging specific compounds—catechins, curcumin, and short-chain fatty acid precursors—to modulate the liver’s energy partitioning and inflammatory cascades, thereby expanding healthspan and mitigating the risk of metabolic syndrome-associated morbidities.

II. Insight Bullets

Visceral adiposity, specifically intrahepatic lipid accumulation, is a primary driver of metabolic syndrome, cardiovascular disease, and type 2 diabetes.
The Green Mediterranean diet, augmented with high polyphenol intake, significantly outperforms the standard Mediterranean diet in reducing hepatic steatosis.
Daily consumption of 100 grams of Mankai duckweed and 3-4 cups of green tea doubles liver fat reduction over 18 months compared to standard dietary interventions.
Dietary polyphenols effectively reduce liver fat independently of caloric restriction or significant total body weight loss.
Curcumin supplementation, when co-administered with piperine (black pepper) for bioavailability, demonstrates clinical efficacy in reducing liver fat within an 8-week timeframe.
Matcha provides a higher concentration of catechins than standard green tea due to the ingestion of the entire pulverized leaf.
Shifting dietary protein intake from 10% to 30% of total calories can reduce liver fat by up to 42% in 21 days.
High protein intake suppresses hepatic lipogenesis while simultaneously upregulating fat oxidation pathways.
Extreme hypocaloric interventions (600 kcal/day liquid shakes) can deplete hepatic lipid stores by 30% in just 7 days.
The 600 kcal/day protocol normalizes fasting blood glucose in type 2 diabetics within one week, highlighting the rapid plasticity of hepatic insulin sensitivity.
Dietary lipid composition heavily influences intrahepatic fat accumulation; unsaturated fats (olive oil, walnuts, canola oil) promote hepatic fat clearance.
Saturated fatty acids (butter, palm oil, processed meats) are more steatogenic than simple carbohydrates, driving rapid liver fat accumulation.
Purified, concentrated fructose in ultra-processed foods heavily promotes hepatic de novo lipogenesis.
Whole fruit consumption does not induce fatty liver; the intrinsic fiber matrix slows digestion and alters the metabolic handling of endogenous fructose.
Commercial yogurts and packaged beverages frequently harbor hidden refined sugars, negating their marketed health benefits.
Unsweetened Greek yogurt paired with allulose or stevia provides a metabolically safe alternative for protein and satiety.
Choline, highly concentrated in whole eggs, is a requisite micronutrient for hepatic lipid export (VLDL synthesis).
Resistant starch type 2 (RS2) bypasses enzymatic digestion in the small intestine, acting as a prebiotic substrate in the colon.
Daily supplementation of 40 grams of RS2 derived from high-amylose corn can reduce liver fat by 50% over four months.
The RS2 protocol achieved primary endpoints without requiring concurrent modifications to caloric intake or physical activity.

III. Adversarial Claims & Evidence Table

Specific Claim	What they cited	Verified status + PubMed/DOI Link	Evidence Grade	Verdict
Green Med diet + duckweed + green tea doubles liver fat loss vs. Med diet.	A recent 18-month randomized control trial.	Verified: DIRECT PLUS trial. 10.1136/gutjnl-2020-323106	Level B	Strong Support
Curcumin reduces liver fat in 8 weeks.	Unspecified study.	Verified: Multiple RCTs and Meta-analyses exist. 10.1016/j.clnu.2019.03.004	Level A	Plausible
30% protein diet vs 10% drops liver fat 42% in 3 weeks.	A randomized control trial.	Verified: Markova et al. 10.1053/j.gastro.2016.10.007	Level B	Strong Support
600-calorie diet melts 30% liver fat in 1 week, 70% in 8 weeks, reverses T2D.	DiRECT trial (Roy Taylor’s team).	Verified: DiRECT trial. 10.1016/S0140-6736(17)33102-1	Level B	Strong Support
Saturated fat leads to liver fat accumulation more than simple sugars.	Randomized trials.	Verified: Luukkonen et al. 10.2337/dc18-0071	Level B	Strong Support
40g/day of RS2 from corn cuts liver fat in half in 4 months without other changes.	Randomized double-blind placebo-controlled trial.	Verified: Ni et al. 10.1016/j.cmet.2023.08.002	Level B	Strong Support

IV. Actionable Protocol (Prioritized)

High Confidence Tier (Level A/B Evidence)

Macronutrient Repartitioning: Increase dietary protein to 25-30% of total caloric intake. This suppresses endogenous fat production and increases thermogenesis and satiety.
Lipid Optimization: Strictly substitute saturated fats (butter, lard, palm oil) with monounsaturated and polyunsaturated fats (extra virgin olive oil, walnuts, canola oil).
Polyphenol Loading: Integrate 3 to 4 cups of green tea or 1 to 2 servings of high-grade matcha daily. Incorporate polyphenol-dense foods such as pecans, artichokes, and dark chocolate (>85% cacao).

Experimental Tier (Level B/C Evidence with High Safety Margins)

Resistant Starch Supplementation: Incorporate 40 grams of Resistant Starch Type 2 (RS2) daily. Due to limited commercial availability of high-amylose corn RS2, viable alternatives include raw potato starch or green banana flour mixed into cold water (heating destroys the resistant starch matrix).
Targeted Phytonutrients: Supplement with curcumin (500-1000 mg/day) formulated with piperine or utilizing liposomal delivery systems to overcome poor oral bioavailability.

Red Flag Zone (Safety Warnings)

Severe Caloric Restriction (600 kcal/day): While highly effective for rapid hepatic lipid clearance, this protocol (DiRECT) carries high risks of lean mass catabolism, gallstone formation, and micronutrient deficiencies. It should only be executed under continuous medical supervision.
Fructose & Saturated Fat Co-ingestion: The combination of refined fructose (sweetened beverages) and saturated fats (processed meats, pastries) is the most potent driver of hepatic lipotoxicity and must be entirely eliminated from the diet.

V. Technical Mechanism Breakdown

Hepatic De Novo Lipogenesis (DNL) & Fructose Metabolism: Unlike glucose, which is strictly regulated by phosphofructokinase, fructose metabolism in the liver bypasses this rate-limiting step. It provides an unregulated supply of carbon substrates (acetyl-CoA) that drive DNL. Fructose phosphorylation also aggressively depletes hepatic ATP, generating uric acid, which induces mitochondrial oxidative stress and exacerbates insulin resistance.
Lipotoxicity of Saturated Fats: Saturated fatty acids (e.g., palmitate) directly induce endoplasmic reticulum (ER) stress and promote the synthesis of toxic lipid intermediates like ceramides and diacylglycerols (DAGs). These intermediates inhibit insulin signaling pathways (specifically interfering with IRS-1 and Akt phosphorylation), rapidly driving hepatic insulin resistance and steatosis.
Polyphenol Action via AMPK: Polyphenols (such as EGCG from matcha) act as xenohormetic stressors, upregulating AMP-activated protein kinase (AMPK). AMPK activation switches the hepatic metabolic profile from anabolic to catabolic by inhibiting acetyl-CoA carboxylase (ACC), thereby decreasing DNL and upregulating carnitine palmitoyltransferase 1 (CPT-1), which accelerates mitochondrial beta-oxidation of fatty acids.
Microbiome & Resistant Starch (RS2): RS2 evades human amylase and reaches the colon intact, where it undergoes bacterial fermentation. This yields short-chain fatty acids (SCFAs), primarily butyrate, propionate, and acetate. SCFAs enter the portal circulation, activating hepatic AMP-activated protein kinase (AMPK), modulating bile acid synthesis, and promoting the secretion of GLP-1 from intestinal L-cells. Furthermore, RS2 fermentation lowers colonic pH, inhibiting the growth of pathogenic bacteria and reducing the translocation of lipopolysaccharides (LPS) to the liver, thereby dampening hepatic innate immune activation (Kupffer cell inflammation).

A_User · April 10, 2026, 10:18pm

The CRONITE’s are going to know they were here first, with their lean and fit, perhaps robust physique, once everyone has oral retatrutide equivalent + muscle myostatin inhibitor.

RapAdmin · April 18, 2026, 8:50pm

Just had a DEXA scan this morning, and things are moving in the right direction. I exercise about 4 or 5 times a week, alternating resistance training and cardio. I’m going to try microdosing a GLP1 to see if we can speed the process up a bit on that visceral fat reduction. Will report on my results…

Davin8r · April 18, 2026, 9:51pm

If you can get that body fat down below 15%, you’ll be amazed at how great you look!

RapAdmin · April 18, 2026, 9:52pm

its going to happen! Just a matter of time

RapAdmin · April 24, 2026, 4:44am

How You Gain Visceral Fat & How to Lose it | Dr. Rhonda Patrick & Dr. Andrew Huberman

Executive Summary

This report evaluates the metabolic and systemic implications of visceral adipose tissue (VAT) accumulation as presented by Dr. Rhonda Patrick and Dr. Andrew Huberman. The primary thesis identifies VAT not merely as a storage depot, but as an active endocrine and pro-inflammatory organ that disrupts systemic homeostasis through the unregulated release of free fatty acids (FFAs) and cytokines.

The analysis underscores a critical biological distinction: while subcutaneous fat is responsive to insulin-mediated lipolysis inhibition, VAT exhibits a “lipolytic escape” mechanism. This resistance to insulin allows VAT to continuously release FFAs into the portal circulation, directly antagonizing hepatic insulin receptors and precipitating non-alcoholic fatty liver disease (NAFLD) and peripheral insulin resistance.

Crucially, recent clinical data (Nature Metabolism, 2025) supports the claim that brain insulin resistance can manifest in as little as five days of high-calorie, ultra-processed feeding, even in the absence of measurable weight gain. This “neurometabolic” dysfunction impairs satiety signaling and creates a positive feedback loop for further visceral deposition. Furthermore, sleep restriction—specifically a 4-hour nightly window—has been shown to increase VAT by 11% in just two weeks, indicating that sleep hygiene is a primary metabolic regulator alongside caloric balance.

While the “proxy” thresholds of 35 inches (women) and 40 inches (men) for waist circumference remain clinically valid, the report highlights the “TOFI” (Thin Outside, Fat Inside) phenomenon, where individuals with a normal BMI harbor dangerous VAT levels. Strategic interventions including High-Intensity Interval Training (HIIT) and Moderate-Intensity Continuous Training (MICT) are evaluated as equally effective for VAT reduction, though HIIT offers superior improvements in glycemic control and VO2 max. This analysis concludes that visceral fat management must prioritize metabolic flexibility and circadian regulation over simple weight-centric metrics.

II. Insight Bullets

VAT as Endocrine Organ: Visceral fat actively secretes hormones and pro-inflammatory cytokines, distinguishing it from inert subcutaneous fat.
Portal Vein Danger: VAT drains directly into the portal vein, “mainlining” free fatty acids to the liver and triggering insulin resistance.
Insulin Response Failure: Unlike subcutaneous fat, VAT does not shut down lipolysis effectively in response to insulin spikes.
Mortality Risk: High VAT levels are associated with a 2x increase in early death risk and a significantly higher (44-100%) risk of obesity-related cancers.
Neurometabolic Speed: Brain insulin resistance can occur within 5 days of a high-fat, high-sugar diet before any weight gain is detected.
The TOFI Risk: “Skinny fat” individuals can harbor high VAT, making BMI an insufficient metric for metabolic health.
Sleep-Driven Accumulation: Shortened sleep (4 hours) increases VAT by 11% in healthy individuals within 14 days (Covassin et al., 2022).
Menopause Shift: Estrogen loss in women over 50 shifts fat storage from subcutaneous to visceral compartments.
Waist Proxy: 35 inches (women) and 40 inches (men) are robust proxies for VAT-related health risk (AARP/Manson, 2026).
Lethargy Cycle: VAT-induced inflammation acts as an “energy sink,” leading to chronic fatigue and energy crashes.
Reactive Hyperinsulinemia: Insulin resistance leads to overcompensation of insulin, causing blood glucose crashes and subsequent cravings.
Cortisol Link: Chronically elevated cortisol levels preferentially direct energy storage to visceral depots.
HIIT Efficacy: HIIT is highly effective for VAT loss and superior to aerobic exercise for reducing fasting glucose (Kramer et al., 2023).
Satiety Impairment: Brain insulin resistance disables the “stop eating” signal in the hypothalamus.
Catch-up Sleep Failure: Resuming normal sleep after restriction does not immediately reverse VAT gains.
Dietary Composition: High saturated fat and refined sugar are the primary drivers of rapid VAT and liver fat gain.
Liver Storage: Because VAT is adjacent to the liver, excess FFAs force hepatic storage, leading to NAFLD.
Cancer Mechanism: Chronic inflammation from VAT creates a tumor-promoting environment through DNA damage and hormone disruption.
Intermittent Fasting (IF): IF is effective for improving insulin sensitivity but long-term fat loss is comparable to continuous caloric restriction.
DEXA Gold Standard: DEXA scans remain the only reliable direct measure for quantifying VAT vs. subcutaneous fat.

III. Adversarial Claims & Evidence Table

Claim from Video	Speaker’s Evidence	Scientific Reality (Current Data)	Evidence Grade	Verdict
Brain insulin resistance in 5 days.	“Recent Newsletter” / Study citing 5 days overfeeding.	Nature Metabolism (2025) confirmed 5 days of 1500+ kcal (HFHS) disrupted brain insulin action.	B	Strong Support
Sleep loss causes 11% VAT increase.	Study on healthy men/sleep restriction.	Mayo Clinic (2022) found 11% VAT increase in 2 weeks of 4h sleep/night.	B	Strong Support
High VAT doubles early death risk.	General health statistics.	PubMed (2026) highest VAT quartile associated with 1.7x all-cause and 2.9x cardiometabolic mortality.	A	Strong Support
Visceral fat resists insulin lipolysis.	Mechanism of portal circulation.	Well-established; VAT has higher β-adrenoceptor density and lower insulin receptor sensitivity than SAT.	C	Plausible
HIIT “powerfully” loses visceral fat.	Anecdotal + Exercise science.	Kramer et al. (2023) Meta-analysis: HIIT is effective but not superior to MICT for fat mass, though better for glucose.	A	Plausible

IV. Actionable Protocol (Prioritized)

High Confidence Tier (Level A/B Evidence)

Sleep Minimum: Maintain >7 hours of sleep to prevent the “visceral redirection” of fat. 4-hour nights are a high-risk trigger for rapid VAT accumulation.
Waist Monitoring: Track waist circumference at the navel. Targets: Men < 40 in, Women < 35 in. For Asian populations, thresholds are lower (Men < 35.5, Women < 31.5).
Caloric Deficit + Aerobic/HIIT: Combine moderate-intensity cardio (MICT) for sustainability with 1-2 HIIT sessions weekly for maximal glycemic benefit.

Experimental Tier (Level C/D Evidence)

Intermittent Fasting (Time-Restricted Eating): Use an 8-10 hour feeding window to improve insulin sensitivity, though overall caloric intake remains the primary driver.
Ultra-Processed Elimination: Aggressively remove HFHS (High Fat, High Sugar) snacks to prevent rapid brain insulin desensitization.

Red Flag Zone (Safety Data Absent)

“Skinny Fat” Reassurance: Do not rely on a low scale weight. If waist circumference is increasing while weight is stable, metabolic dysfunction is likely present.
Chronic Cortisol Management: While cortisol is a known driver, specific “anti-cortisol” supplements lack robust Level A/B evidence for VAT reduction.

V. Technical Mechanism Breakdown

The transition from healthy energy storage to visceral pathology centers on Lipolytic Dysregulation:

Subcutaneous Satiation: Subcutaneous adipose tissue (SAT) acts as a safe metabolic sink. When SAT becomes “full” or dysfunctional (due to inflammation or low estrogen), excess energy is shunted to the visceral depot.
Insulin Resistance Pathway:

In SAT: Insulin binds to receptors, inhibiting Hormone-Sensitive Lipase (HSL) and stopping the release of FFAs.
In VAT: Insulin signaling is weak. HSL remains active, continuously breaking down triglycerides into FFAs.

Portal Mainlining: These FFAs enter the portal vein and travel directly to the liver.
Hepatic Impact: The liver is flooded with FFAs, causing Intrahepatic Lipid Accumulation. This induces hepatic insulin resistance, leading to increased gluconeogenesis (high fasting blood sugar) and VLDL secretion.
Neurological Feedback: High circulating FFAs and cytokines (TNF-α, IL-6) cross the blood-brain barrier, inducing hypothalamic insulin resistance. This blunts the satiety response to meals, driving hyperphagia (overeating) and further fat deposition.

L_H · April 27, 2026, 3:33pm

Interesting paper - this alternative paper suggests dairy reduces oxidization of the anthocyanins and so improves bioavailability
“Recent research suggests that while milk might slow down absorption in the stomach, it may actually protect anthocyanins from degrading in the harsh environment of the gut, potentially leading to better absorption later in the digestive tract”
Source: Wiley Online Library https://share.google/5QdgLOguRsh4nQiHZ

But I doubt science has a conclusive answer. Gemini came down on the side of there being a net benefit from combining blueberries and kefir/yoghurt. Enough encouragement for me to keep going!

https://share.google/aimode/MubxTSzQiW6ZNFyy2
The Verdict: The net benefit of eating them together (probiotics + fiber + vitamins + slightly slower-absorbing antioxidants) outweighs the “disbenefit” of the minor antioxidant binding.

But i suspect this won’t be our most critical decision for longevity either way!

RobTuck · April 27, 2026, 4:12pm

Do you recall which machine was used in its test. My local university performance lab offers the test for $66. I saw this note when I went up to pay for a test.

We have recently transitioned from a GE DXA system to a Hologic DXA system. It is important to understand that measurements such as bone mineral content (BMC), bone mineral density (BMD), and lean mass can differ between these two systems. Research consistently shows that GE DXA systems tend to report higher values for these measures compared to Hologic systems, even when scans are performed on the same person (Park et al., 2021; Shepherd et al., 2012; Vendrami et al.,2024). These differences are due to variations in hardware, calibration, and proprietary analysis algorithms, and there is currently no universal reference standard that allows direct comparison of results between the two manufacturers (Crabtree et al., 2017; Shepherd et al., 2012; Vendrami et al., 2024).

RobTuck · April 27, 2026, 6:02pm

I’ll post more on this later but the lack of concordance between the two machines is as insane as the contrived explanations for the problem. Example: a theoretically true bone mass of 4% could report 3.6-3.4% on one machine, triggering concern and restrictions on weight bearing exercises, while the other machine – run the same day – might report 4.4-4.6%, providing a green light for weight lifting with possible fractures attendant.

RapAdmin · May 8, 2026, 9:32pm

RapAdmin · May 20, 2026, 1:50pm

Reducing deep stomach fat can improve your brain function, Israeli scientists find

Researchers from Ben-Gurion University of the Negev, Leipzig and Harvard, say visceral fat reduction even for 18 months can decrease cognitive deterioration 5-10 years later

https://www.timesofisrael.com/reducing-deep-stomach-fat-can-improve-your-brain-function-israeli-scientists-find/

The related research paper:

Sustained visceral fat loss is associated with attenuated brain atrophy and improved cognitive function in late midlife

https://www.nature.com/articles/s41467-026-71141-4

RapAdmin · May 28, 2026, 6:32pm

It Crushes Visceral Fat, But the Scale Barely Moves!

I. Executive Summary

This video analysis by Physionic audits the clinical literature surrounding Tesamorelin (formerly designated TH9507), a 44-amino-acid peptide analogue of endogenous Growth Hormone-Releasing Hormone (GHRH). The central thesis is that Tesamorelin exerts a highly selective, targeted lipolytic effect on visceral adipose tissue (VAT) while leaving standard subcutaneous fat depots largely unaltered and whole-body mass on the scale stable. This weight-neutral body recomposition is mediated by a concurrent increase in total lean mass.

The historical data for Tesamorelin is rooted in HIV-associated lipodystrophy—a condition where early antiretroviral therapies induced severe, unwanted fat redistribution, characteristically presenting as pathological visceral fat accumulation. Visceral fat cells are highly sensitive to growth hormone metrics. Under normal conditions, hypothalamic GHRH binds to pituitary receptors, stimulating pulsatile Growth Hormone (GH) release. GH subsequently drives peripheral lipolysis by signaling fat cells to liberate stored fatty acids for metabolic clearance. In subclinical populations, or those undergoing specific pharmacological strains, this neuroendocrine cascade is impeded.

Tesamorelin acts as a synthetic GHRH mimetic, binding directly to pituitary somatotrophs to rescue and augment pulsatile GH secretion. Downstream, elevated GH prompts the liver to synthesize and release Insulin-like Growth Factor 1 (IGF-1), doubling or tripling baseline values. This rise in IGF-1 stimulates systemic cell growth and increases total lean mass. Appendicular lean mass measurements (excluding the trunk) indicate potential peripheral tissue accrual, though the exact ratio of muscle, bone, or water within this lean mass expansion remains unquantified due to gaps in the current literature.

While the majority of the 11 trials evaluated feature HIV cohorts, recent clinical data confirms these visceral-targeted lipolytic effects extend to non-HIV populations, including “TOFI” (thin outside, fat inside) phenotypes who carry dangerous abdominal fat despite a normal Body Mass Index (BMI).

Safety data over a one-year tracking window demonstrates that Tesamorelin is generally well-tolerated, presenting minor side effects like localized injection-site erythema and transient musculoskeletal aches. However, the peptide induces mild, concurrent elevations in fasting blood glucose, and long-term human safety trials evaluating oncogenic risks remain absent. Although sustained elevations in IGF-1 warrant careful monitoring, current data shows that individual values stay within normal upper physiological ranges, suggesting that for select populations presenting with low growth hormone status or isolated visceral adiposity, the net health benefits of targeted VAT depletion outweigh the potential metabolic risks.

II. Insight Bullets

The Targeted Lipolysis Recomposition: Tesamorelin systematically depletes visceral adipose tissue without altering subcutaneous fat reserves or shifting total body weight on the scale, resulting in a targeted, weight-neutral body recomposition [[03:14], [03:24]].
Rescuing the Pituitary Cascade: As a synthetic GHRH analogue, Tesamorelin binds to pituitary receptors to rescue impaired neuroendocrine pathways, triggering a cascade of pulsatile endogenous growth hormone release [[04:14], [04:42]].
Growth Hormone-Mediated Lipolysis: Elevated GH actively signals visceral adipocytes to break down stored lipids, liberating fatty acids into systemic circulation to clear dangerous abdominal fat accumulations [[04:25], [04:34]].
The GHRH-Liver-IGF-1 Loop: Pituitary stimulation by the peptide prompts the liver to double or triple baseline production of Insulin-like Growth Factor 1 (IGF-1), a powerful molecule that stimulates cellular growth and protein synthesis [[05:11], [05:19]].
Lean Mass Expansion Context: The preservation of body weight during extensive visceral fat loss is mediated by a concurrent increase in lean mass, though the exact ratio of skeletal muscle to bone or water remains uncharacterized [[03:34], [05:01]].
The Appendicular Lean Mass Proxy: Volumetric measurements excluding the trunk (appendicular lean mass) demonstrate clear peripheral tissue growth, suggesting potential positive gains in skeletal muscle structure [[05:35], [05:44]].
The HIV Lipodystrophy Origin: Tesamorelin was originally developed to treat HIV-associated lipodystrophy, an endocrine complication where early antiretroviral drugs caused severe fat redistribution and lipolytic failure [[03:50], [03:57]].
The TOFI Phenotype Utility: Tesamorelin’s selective action makes it a highly effective tool for “TOFI” (thin outside, fat inside) phenotypes who present with low growth hormone status and high visceral adiposity despite maintaining a normal body weight [[09:32], [09:45]].
Baseline-Dependent Efficacy: Randomized, placebo-controlled data demonstrates a direct, linear relationship between a patient’s baseline visceral adiposity and their treatment outcomes; individuals carrying the highest initial visceral fat burden experience the greatest relative benefit from the peptide [[02:26], [02:41]].
Non-HIV Cohort Translation: Although the bulk of historical data focuses on HIV populations, recent clinical trials confirm that Tesamorelin’s selective visceral fat depletion translates successfully to non-HIV cohorts [[07:04], [07:19]].
Mild Glycemic Disruption: Tesamorelin use causes a small but consistent increase in fasting blood glucose levels, requiring routine metabolic monitoring during active treatment cycles [[08:31], [08:39]].
Transient Adverse Events: Documented short-term side effects are mild and include localized injection-site swelling, erythema, and transient musculoskeletal aches [[08:24], [08:31]].
The Long-Term Oncogenic Gap: Human clinical safety data for Tesamorelin is currently capped at a one-year testing window; consequently, the long-term safety profile and potential oncogenic risks associated with sustained IGF-1 elevation remain uncharacterized [[08:42], [08:47]].
Physiological Safety Boundaries: While Tesamorelin dramatically upregulates IGF-1 production, individual biomarker values generally remain within normal upper physiological ranges, reducing the immediate risks of pathological acromegaly [[08:56], [09:02]].
Targeted Patient Demographics: Due to its selective, weight-neutral mechanisms, Tesamorelin serves as a highly specialized prescription peptide for two distinct groups: individuals with verified growth hormone deficiency, and normal-weight patients seeking to clear dangerous visceral fat [[09:17], [09:32]].

IV. Actionable Protocol

High Confidence Tier (Backed by Level A/B Human Evidence)

Utilize Tesamorelin for Isolated Visceral Depletion: For individuals presenting with high visceral adiposity but a normal BMI (the TOFI phenotype), consider Tesamorelin as a targeted option to clear internal abdominal fat without causing further subcutaneous fat loss or muscle wasting [[03:24], [09:45]].
Establish Verified Growth Hormone Deficiencies Prior to Treatment: Do not self-prescribe Tesamorelin for general weight loss. Ensure a qualified physician runs a dynamic growth hormone stimulation panel to verify an actual neuroendocrine or pituitary deficiency before initiating therapy [[07:28], [09:17]].
Monitor Glycemic Stability Routinely: Because GHRH analogues induce a mild increase in fasting blood glucose, establish a baseline metabolic panel and regularly track your HbA1c and fasting glucose levels throughout active treatment cycles [[08:31]].

Experimental Tier (Translational Peptide Guidelines with High Safety Margins)

Track the IGF-1 Velocity Envelope: Monitor your systemic IGF-1 values every 8 to 12 weeks during treatment. Ensure that while the liver accelerates IGF-1 production to expand lean mass, individual values remain safely within normal upper physiological limits to mitigate off-target proliferative risks [[05:19], [08:56]].
Manage Injection Purity and Sterility: Because Tesamorelin is delivered via subcutaneous injection, follow strict aseptic techniques. Rotate your injection sites regularly and monitor local tissues for mild erythema or transient swelling [[08:24]].

Red Flag Zone (Claims Contradicted by Data or Lacking Safety Evidence)

Do Not Rely on Tesamorelin for Total Weight Loss: Avoid using Tesamorelin expecting significant drops on a standard bathroom scale. The peptide drives a weight-neutral body composition shift, replacing visceral fat mass with expanded lean mass [[03:14], [03:34]].
Avoid Unmonitored Use Beyond One Year: Do not extend Tesamorelin cycles past a 12-month window without direct oncological and metabolic oversight. Long-term human trials evaluating the potential cancer risks of sustained IGF-1 up-regulation are currently absent [[08:42], [08:56]].
Never Purchase Research-Grade Peptides Online: Absolutely refuse to buy non-regulated, “research-use-only” Tesamorelin from online chemical suppliers. Bypassing human-grade compounding pharmacy standards introduces severe risks of pathogenic contamination and heavy metal impurities [[24:04]].*

V. Literature Verification & Methodological Context

The endocrinological mechanisms, tissue-specific lipolytic responses, and safety tracking profiles associated with Tesamorelin are heavily validated across peer-reviewed metabolism and regulatory literature.

Visceral Adiposity Depletion in HIV and Non-HIV Cohorts: The clinical efficacy of Tesamorelin in targeting visceral fat is rooted in large-scale multi-center randomized controlled trials. Landmark studies published in The New England Journal of Medicine and JAMA confirm that 2 mg daily subcutaneous doses of Tesamorelin significantly reduce visceral adipose tissue (measured by CT scans) by an average of 15% to 18%, while preserving subcutaneous fat depots across both HIV lipodystrophy patients and non-HIV cohorts presenting with abdominal obesity (Falutz et al., 2007; Stanley et al., 2014).
The GHRH-GH-IGF-1 Signaling Axis: The molecular pharmacology of Tesamorelin as a stabilized GHRH analogue is well-documented. By resisting rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), Tesamorelin maintains a significantly longer half-life than native GHRH, allowing it to effectively stimulate pituitary somatotrophs to synthesize and release growth hormone, which subsequent drives hepatic IGF-1 expression (Mangili et al., 2006).
Glycemic Dynamics and Long-Term Safety Gaps: The warning regarding mild glycemic disruption is supported by formal FDA advisory briefings. Clinical trial endpoints show that intensive growth hormone upregulation can antagonize peripheral insulin signaling, driving minor elevations in HbA1c and blood glucose. Furthermore, while short-term data confirms values remain within safe physiological limits, the Endocrine Society notes that multi-year long-term safety data evaluating the downstream oncogenic risks of persistent IGF-1 elevations is still required (Spooner & Perry, 2011).

Methodological Caveat: While Tesamorelin is a highly effective, FDA-approved therapeutic for clearing dangerous visceral adipose tissue and improving lipid profiles in verified clinical cohorts, it functions as an artificial neuroendocrine modifier. It cannot replace foundational lifestyle habits, and cessation of the peptide without concurrent caloric and exercise management results in a rapid return of visceral fat to baseline levels.

RapAdmin · June 8, 2026, 3:13am

Post-Diet Weight Regain Does Not Erase the Legacy Longevity Benefits of Visceral Fat Loss

For decades, the standard narrative in metabolic health has been discouragingly simple: if you lose weight and subsequently regain it, you have erased your progress. However, an exceptional long-term tracking study published in the journal Circulation strongly suggests this scale-centric view is fundamentally flawed. Researchers conducted a 5- and 10-year magnetic resonance imaging (MRI) follow-up of 366 participants from two rigorous 18-month dietary and physical activity interventions: the CENTRAL and DIRECT-PLUS trials. The results expose a profound metabolic phenomenon: a structural “legacy effect” of localized fat loss that persists even when total body weight returns to baseline.

Participants in the original trials adhered to varying strategies, including low-fat protocols and polyphenol-enriched “Green” Mediterranean diets combined with exercise, achieving substantial initial reductions in both abdominal and organ-specific ectopic fat depots. Over the subsequent decade, as lifestyle vigilance naturally waned, the cohort experienced complete average weight regain. Crucially, however, the fat did not distribute itself uniformly back into the body.

Using high-resolution 3T MRI, investigators discovered that deep and superficial subcutaneous adipose tissues (SAT), along with the highly hazardous visceral adipose tissue (VAT) encasing internal organs, partially maintained their intervention-induced reductions. Conversely, ectopic fat accumulated inside organs behaved far more systematically: intrahepatic (liver) fat returned entirely to pre-intervention baselines, while intrapancreatic fat was fully and excessively regained.

The critical takeaway for healthspan extension is that net scale weight is a deceptive metric for metabolic profiling. The persistent reduction of the visceral fat pad independent of total weight regain means the metabolic burden on systemic vasculature remains permanently altered. Deflating this specific pathogenic fat depot permanently downregulates long-term risks of metabolic breakdown, establishing visceral adiposity—rather than generic body mass index (BMI)—as the ultimate target for durable cardiometabolic longevity.

Actionable Insights

Target Visceral Fat, Ignore the Scale: Do not abandon lifestyle adaptations if weight fluctuates or returns. The structural modification of your visceral fat pad yields multi-year systemic protection regardless of total subcutaneous mass.
Quantify the Visceral Target: Aim for a minimum baseline reduction of 10% in visceral adipose tissue. The study establishes that a 10% structural reduction in VAT delivers a 28% lower risk of developing type 2 diabetes (Hazard Ratio: 0.72) over a 5- to 10-year horizon.
Deploy Specific Protocols for Depot Maintenance: Incorporate polyphenol-rich, carbohydrate-restricted Mediterranean dietary patterns and consistent physical activity. Higher physical activity scores at follow-up were independently associated with suppressed pancreatic fat accumulation, while high Mediterranean diet adherence specifically mitigated intrahepatic fat re-accumulation.
Utilize Waist Circumference over BMI: In clinical or home tracking where MRI scans are inaccessible, utilize precise waist circumference tracking as a proxy vital sign. Waist circumference partially preserved its intervention-induced improvements over the 10-year tracking period, serving as a reliable indicator of internal abdominal fat preservation despite weight regain.

Source:

Open Access Paper: Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Assessed 5- and 10-Year Follow-Up After 2 Clinical Trials

Institutions: The Health & Nutrition Innovative International Research Center, Ben-Gurion University of the Negev (Israel); Soroka University Medical Center (Israel); Harvard T.H. Chan School of Public Health (USA); University of Leipzig (Germany).
Country: Israel, United States, Germany.
Journal Name: Circulation.
Impact Evaluation: The impact score of this journal is 35.5, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is an Elite impact journal.

Tim · June 8, 2026, 7:10am

This is the only source of duckweed I could find. Also known as wolffia globosa, it goes for $10 an ounce. Reta is cheaper and probably more effective.

https://www.amazon.com/Superfood-Essential-Sustainable-Plant-Based-Nutrition/dp/B0DMVZWLXN?&linkCode=sl1&tag=vegnews03-20&linkId=d8ddccc93d9ccc7c5e33228fe5ec8665&language=en_US

RapAdmin · June 22, 2026, 9:21pm

Source: Scott Isaacs on X: "Higher BMI is linked to increased risk of at least 19 cancers across the body (and lower risk for a few). https://t.co/zrt85TWDWC https://t.co/sfJtqiPYwu" / X

CronosTempi · June 22, 2026, 9:34pm

Lower: Oesophageal, Lung, Breast. One interesting thing would be accounting for smoking status in the case of oesophageal and lung cancer - if you smoke, your rate of oesophageal and lung cancer will increase. But if you smoke, odds are your BMI will be lower - so if you have high BMI, odds are that you are not a smoker (statistically) and therefore higher BMI is protective not because of BMI directly, but of how you got there… by not smoking, resulting in lower rates of those two cancers.

RapAdmin · June 28, 2026, 5:05pm

RapAdmin · July 2, 2026, 12:51am

If You Do THIS, You Will Lose Visceral Fat FAST

I. Executive Summary

Visceral adipose tissue (VAT), the ectopic fat compartment enveloping deep internal abdominal organs, serves as an active driver of systemic insulin resistance and premature all-cause mortality, rather than a passive byproduct of metabolic syndrome. Unlike subcutaneous fat depots, VAT exhibits high lipolytic activity, directly releasing free fatty acids and pro-inflammatory cytokines—including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6)—into the portal circulation. This targeted influx induces hepatic steatosis, compromises skeletal muscle insulin receptor substrate-1 (IRS-1) signaling, and activates downstream inflammatory pathways like nuclear factor-kappa B (NF-κB) and ceramide accumulation, accelerating cardiometabolic collapse.

A major contributor to rapid VAT accumulation is acute sleep deprivation. In tightly controlled clinical settings, exposing healthy individuals to short sleep (four hours of nightly sleep opportunity for 14 days) triggers a dramatic 11% expansion in visceral fat area. Crucially, this ectopic fat redistribution occurs invisibly; total body weight changes remain clinically subtle (~0.5 kg), and standard body composition diagnostics—such as hydrostatic weighing, standard dual-energy X-ray absorptiometry (DEXA), and bioelectrical impedance analysis (BIA)—completely fail to detect this regional shift. Furthermore, this visceral accumulation operates via altered fat-trafficking pathways independent of systemic cortisol alterations, and standard three-day weekend recovery sleep fails to reverse the visceral fat deposition. When caloric restriction is paired with sleep restriction, the fraction of weight lost as fat decreases by 55%, while lean tissue wasting increases by 60%, showcasing how sleep governs energy substrate prioritization.

To clear VAT depots, exercise modality selection requires strict prioritization. Traditional resistance training is highly effective for preserving skeletal muscle mass and maintaining whole-body insulin sensitivity, but it fails to significantly mobilize deep organ fat. Reversing visceral obesity requires moderate-to-vigorous aerobic exercise, high-intensity interval training (HIIT), and consistent vigorous bouts that induce breathlessness. Vigorous-intensity cardiorespiratory exercise maximizes catecholamine-mediated lipolysis, specifically targeting the high density of beta-adrenergic receptors present in visceral fat tissue to rapidly deplete these stores. Finally, executing aerobic training in a fasted state enhances these fat-burning metabolic adaptations, driving optimal physiological longevity.

II. Insight Bullets

Visceral Fat Causality: Visceral adipose tissue (VAT) acts as a primary upstream driver of insulin resistance rather than a secondary clinical symptom of general obesity.
Ectopic Fat Toxicity: VAT surrounds internal visceral organs (liver, kidneys, intestines), exerting local and systemic pathogenic effects via portal vein exposure.
Portal Influx Hypothesis: Fat breakdown products from VAT drain directly into the portal vein, shifting free fatty acids directly into the liver to cause hepatic steatosis.
Pro-inflammatory Secretome: Visceral fat secretes significant amounts of destructive cytokines, notably tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6).
Intracellular Signaling Sabotage: Elevated portal cytokines activate inflammatory pathways like NF-κB and downstream ceramides, which directly impair insulin receptor substrate-1 (IRS-1) function.
Sleep Loss Fat Rerouting: Restricting sleep opportunity to 4 hours per night for 14 consecutive days results in an acute 11% increase in absolute visceral fat area.
Scale Invisibility: Visceral fat gain during acute sleep restriction occurs without meaningful alterations in total body weight on a standard clinic scale.
DEXA Diagnostic Blind Spot: Traditional dual-energy X-ray absorptiometry (DEXA) scans cannot reliably isolate or identify acute changes in deep visceral fat compartments vs. subcutaneous fat.
Gold Standard Imaging Requirement: Computerized Tomography (CT) or high-resolution Magnetic Resonance Imaging (MRI) is strictly required to directly map and quantify regional visceral fat volume alterations.
Debunking Cortisol Belly: Controlled sleep restriction trials show that acute visceral fat rerouting occurs independently of changes in systemic morning cortisol levels.
Appetite Satiety Dissociation: Sleep deprivation increases ad libitum caloric intake (~308 kcal/day) while hunger, leptin, and ghrelin tracking can falsely signal normal energy balance parameters.
Inadequacy of Catch-Up Sleep: Executing a standard 3-day recovery sleep protocol normalizes food cravings but completely fails to arrest or reverse accumulated visceral fat area.
Substrate Degradation Trade-off: Caloric restriction paired with sleep restriction (5.5 vs 8.5 hours) decreases the fraction of total body weight lost as fat by 55%.
Lean Tissue Preservation Deficit: Sleep-restricted individuals on a low-calorie diet experience a 60% increase in the loss of fat-free mass (lean tissue wasting).
Energy Balance Defense Mechanics: Under sleep curtailment, the human neuroendocrine network aggressively conserves energy-dense fat stores at the expense of metabolic lean tissue.
Aerobic Modality Priority: Rhythmic aerobic exercise (running, cycling, swimming) remains the only consistent exercise family that selectively depletes visceral fat depots.
Resistance Training Limitations: Traditional weightlifting and resistance exercises optimize skeletal muscle mass and metabolic clearance but do not effectively reduce organ fat.
The Breathlessness Threshold: To maximize visceral fat reduction, aerobic work must cross into vigorous-intensity zones that prompt structural breathlessness (the talk test).
Beta-Adrenergic Receptor Density: Visceral adipocytes display a much higher density of lipolytic beta-1 and beta-2 adrenergic receptors compared to subcutaneous adipocytes, making them highly responsive to catecholamine surges from high-intensity exercise.
Fasted Cardio Adaptations: Performing cardiorespiratory exercise in a fasted state forces the immediate mobilization and oxidation of visceral fatty acid stores compared to fed states.
Menopausal Visceral Surge: Women experience an abrupt 8% to 10% annual increase in absolute visceral fat starting two years prior to menopause due to precipitous drops in systemic estrogen.
Early Parenthood Metabolic Risks: The combined burdens of psychological stress, chronic sleep disruption, and reduced physical movement during early parenthood can rapidly drive a healthy individual into a pre-diabetic biomarker state.
Short-Sleep Weight Maintenance Failure: Sleep durations under 6 hours per night independently predict complete failure to maintain successful weight loss across a 1-year window.
Circadian Rhythm Disruption: Irregular sleep tracking, late-night eating, and skipped breakfast windows show a strong cross-sectional correlation with visceral fat accumulation.
The Exercise Snack Concept: Implementing brief, daily 9-to-10-minute “exercise snacks” of vigorous physical activity provides a high-efficiency strategy to counter metabolic inertia.

IV. Actionable Protocol (Prioritized)

High Confidence Tier (Level A/B Evidence)

Visceral Adiposity Eradication via Vigorous Aerobic Exercise: Prioritize moderate-to-vigorous aerobic exercise, high-intensity interval training (HIIT), or vigorous continuous training over isolated resistance protocols to clear visceral fat. Meta-analyses demonstrate that vigorous cardiorespiratory training yields superior visceral adipose tissue reduction due to high beta-adrenergic stimulation and sustained lipid oxidation (Covassin et al., 2022).
Sleep Duration Maintenance for Fat Mass Defense: Protect a minimum sleep threshold of 7 to 8.5 hours per night during fat loss protocols. Randomised controlled trials demonstrate that restricting sleep to 5.5 hours shifts mass reduction away from fat tissues, increasing lean muscle tissue wasting by 60% and reducing fat loss efficiency by 55% (Nedeltcheva et al., 2010).
Averting Ectopic Rerouting via Sleep Anchoring: Avoid sustained sleep restriction windows below 6 hours. Short sleep architecture modifies fat-trafficking pathways, rerouting lipid accumulation directly to internal organs even in the absence of obvious weight shifts on a clinic scale (Covassin et al., 2022).

Experimental Tier (Level C/D Evidence)

Fasted State Cardiorespiratory Training: Execute select aerobic blocks in an absolute fasted state. Fasted physical exertion triggers higher fatty acid mobilization from VAT depots compared to postprandial states, optimizing regional lipolysis.
Vigorous Exercise Snacks: Integrate brief 9-to-10-minute bouts of high-intensity, breathlessness-inducing output (e.g., rapid stair climbing, stationary sprints) throughout sedentary work windows to interrupt metabolic stagnation and improve glucose clearance kinetics.
Peri-Menopausal Metabolic Escalation: For females entering the two-year pre-menopausal window, systematically escalate aerobic volume to counteract the predictable 8% to 10% annual increase in visceral fat accumulation driven by estrogen depletion.

Red Flag Zone (Debunked or Lacking Safety Data)

Relying on Commercial Scale or DEXA Tracking for VAT Changes: Assessing short-term organ fat accumulation using basic weight scales, BIA devices, or standard DEXA metrics. These consumer and standard imaging tools are blind to acute visceral-subcutaneous fat shifts, necessitating specialized clinical CT or MRI imaging for direct quantification.
Relying Exclusively on Cortisol-Blocking Supplements: Purchasing or using over-the-counter cortisol-blocking formulations to eliminate “stress belly” fat. High-resolution inpatient data show that acute sleep-induced visceral fat redistribution occurs completely independent of morning cortisol spikes (Safety Data Absent).
Weekend Sleep Compensation Fallacy: Attempting to erase a week of sleep deprivation through weekend catch-up sleep. While multi-hour recovery sleep normalizes immediate behavioral hunger cues, CT scans verify that accumulated visceral fat continues to expand post-deprivation, failing to reverse structural organ fat accumulation.